Evidence supporting the use of: Human growth hormone
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Human growth hormone (HGH), also known as somatotropin, has a scientifically established role in bone metabolism and growth. Its use in osteoporosis is based on its ability to stimulate osteoblast activity, enhance bone formation, and increase bone mineral density (BMD). Several clinical studies and trials have investigated recombinant HGH therapy in adults with osteoporosis, particularly in those with confirmed growth hormone deficiency (GHD). These studies generally show that HGH can increase bone turnover and BMD, especially in the lumbar spine, and may modestly reduce fracture risk over time. However, the benefits are most pronounced in GHD patients, and less clear for the general osteoporosis population without GHD. HGH is not a first-line treatment for osteoporosis; bisphosphonates, denosumab, and selective estrogen receptor modulators are preferred due to their strong evidence base and favorable risk profiles. HGH therapy is associated with potential side effects, such as edema, joint pain, insulin resistance, and increased cancer risk, limiting its widespread use. Guidelines from major endocrinology societies recommend HGH primarily for osteoporosis in the context of GHD, not for primary or postmenopausal osteoporosis. In summary, while there is scientific evidence supporting the use of HGH for osteoporosis in specific populations (notably those with GHD), its routine use in general osteoporosis management is not widely endorsed, reflected in a moderate evidence rating.

More about Human growth hormone
More about Osteoporosis

Products containing Human growth hormone

We currently have no products on Vitabase that contain this ingredient.